Joint Announcement Regarding a Notice From CFR Pharmaceuticals S.A. ("CFR") ("CFR Notice") to Increase the Total Consideration

Joint Announcement Regarding a Notice From CFR Pharmaceuticals S.A. ("CFR")
("CFR Notice") to Increase the Total Consideration Payable to the Holders of
Adcock Ingram Ordinary Shares in Terms of the Scheme of Arrangement Proposed
Between Adcock Ingram and Adcock Ingram Ordinary Shareholders (Other Than the
Ordinary Shares Held by Adcock Ingram's Wholly Owned Subsidiary); a
Recommendation to Adjourn the General Meetings Scheduled to Take Place on
Wednesday, 18 December 2013; the Intention to Oppose the Complaints Set Out in
the Application Brought by a Consortium Led by the Bidvest Group Limited
("Bidvest") ("Bidvest Application"); and Renewal of Cautionary Announcement

SANTIAGO, Chile, Dec. 13, 2013 (GLOBE NEWSWIRE) -- CFR Pharmaceuticals S.A.
(SSE:CFR), the Chilean multinational emerging markets pharmaceutical company,
leader in specialties and prescription medicines announced today that it had
notified the Adcock Ingram Independent Board of its intention to increase the
total scheme consideration payable to Adcock Ingram ordinary shareholders from
approximately US$1.22 billion to US$1.23 billion. Capitalized terms used but
not defined herein shall have the meaning attributed to them in the Joint
Cautionary Announcement (as defined below) and the Supplementary Circular (as
defined below).

CFR Chief Executive Officer Alejandro Weinstein said: "We are delighted with
the level of support we have received to date including from many new
potential shareholders including sector-specific, emerging market and a number
of leading South African funds who would like to participate in the combined
company.This further reinforces our belief in the compelling rationale behind
our offer and the opportunities it will create for all stakeholders through
the creation of a world-class, pan-emerging markets pharmaceuticals
business."

A supplement to the Combined Circular ("Supplementary Circular") will be
distributed by Adcock Ingram and CFR to Adcock Ingram shareholders in due
course containing, among others, full details of the amendments to the Scheme,
notices of the adjourned General Meetings of Adcock Ingram shareholders to
approve the Scheme, a form of proxy, a form of surrender and transfer, and the
salient dates and times applicable to the Scheme.

In light of the CFR Notice and to give Adcock Ingram ordinary shareholders
sufficient time to consider the amended terms of the Scheme to be set out in
the Supplementary Circular, the Adcock Ingram Independent Board recommended
the adjournment of the General Meetings scheduled to take place on Wednesday,
18 December 2013. If the General Meetings are adjourned, shareholders will be
notified of the new date and times for the adjourned General Meetings,
anticipated to take place by the end of January 2014, which date and time will
be announced on the JSE's SENS.

In addition, having reviewed the application filed by the Bidvest Group
together with its legal advisers and having taken advice from senior counsel,
Adcock Ingram has expressed its view that the allegations and complaints set
out therein are ill founded. Accordingly, Adcock Ingram intends to oppose the
application filed by the Bidvest Group for the reasons set out in the Joint
Cautionary Announcement (as defined below).

You may find an extensive description of the foregoing matters in the joint
cautionary announcement ("Joint Cautionary Announcement") released by Adcock
Ingram and CFR on SENS on December 13, 2013.

Adcock Ingram shareholders are advised that the Joint Cautionary Announcement
is, and the Supplementary Circular will be, available on Adcock Ingram's
website www.adcock.com.

The Supplementary Circular, together with a non-official translation thereof
into Spanish, will be filed with the Superintendencia de Valores y Seguros
("SVS"), as required by the Chilean Securities Market Law, with a copy to all
stock exchanges on which CFR's shares are currently listed in Chile, and
published on CFR's website www.cfr-corp.com.

About CFR

CFR is a multinational pharmaceutical corporation with a leading position in
Latin America and operations in 15 countries in that region. It is the leading
pharmaceutical company in Chile, Colombia and Peru, and also has presence in
Vietnam, Canada and the United Kingdom, focusing on the research, development,
production and sale of branded specialty pharmaceutical products, complex
Injectables, and OTC products. CFR has its origins in 1922 and it was listed
on the Santiago Stock Exchange in 2011 on a successful IPO –more than ten
times oversubscribed– becoming the only publicly traded pan-Latin American
pharmaceutical company. CFR has a market capitalization of US$2 billion,
employs over 7,000 people including 2,000 sales representatives. CFR's growth
strategy focuses on markets in the Americas, Europe and Asia with expansion
plans into emerging markets with high growth potential

GOVERNING LAW AND JURISDICTION

The Scheme is governed by the laws of South Africa. Each of CFR and Adcock
Ingram has consented to the non-exclusive jurisdiction of the South Gauteng
High Court, Johannesburg.

None of this press release, the Circular, the Supplementary Circular, the
Prospectus or the Joint Cautionary Announcement, are intended to, and do not,
constitute, or form part of, an offer to sell or an invitation to purchase or
subscribe for any securities or a solicitation of any vote or approval in any
jurisdiction. None of this press release, the Circular, the Supplementary
Circular, the Prospectus or the Joint Cautionary Announcement, constitutes a
prospectus or a prospectus equivalent document.Investors are advised to read
carefully the Circular and the Supplementary Circular for the full terms and
conditions of the Scheme.Any decision to accept the Scheme or other response
to the proposals should be made only on the basis of the information contained
in the Circular and the Supplementary Circular.

This press release is made in connection of, an offer for the securities of a
South African company by means of the Scheme Circular and the Supplementary
Circular. The offer is subject to disclosure requirements under South African
law that are different from those of the United States and Chile. Financial
statements included in the Scheme Circular, the Supplementary Circular or the
Prospectus have been prepared in accordance with South African accounting
standards that may not be comparable to the financial statements of United
States or Chilean companies.

It may be difficult for you to enforce your rights and any claim you may have
arising under the United States federal securities laws, since Adcock Ingram
is located in South Africa, and all of its officers and directors reside
outside of the United States. You may not be able to sue Adcock Ingram or its
officers or directors in a foreign court, including South African courts, for
violations of the Unites States securities laws. It may be difficult to compel
Adcock Ingram and its affiliates to subject themselves to a United States
court's judgment.

You should be aware that CFR may purchaseordinary shares of Adcock Ingram
otherwise than under the offer, such as in open market or privately negotiated
purchases.

FORWARD-LOOKING STATEMENTS

This press release, the Scheme Circular, the Supplementary Circular, the
Prospectus and the Joint Cautionary Announcement include forward-looking
statements with respect to the financial condition, results of operations and
businesses of CFR and Adcock Ingram and certain plans and objectives of the
boards of CFR and Adcock Ingram with respect to them. These forward-looking
statements can be identified by the fact that they do not relate only to
historical or current facts. Forward-looking statements often use words such
as "anticipate", "expect", "estimate", "intend", "plan", "goal", "believe",
"will", "may", "should", "would", "could", or other words of similar meaning.
These statements are based on assumptions and assessments made by the boards
of CFR and Adcock Ingram in light of their experience and their perception of
historical trends, current conditions, expected future developments and other
factors they believe appropriate. By their nature, forward-looking statements
involve risk and uncertainty, because they relate to events and depend on
circumstances that will occur in the future and the factors described in the
context of such forward-looking statements in this announcement could cause
actual results and developments to differ materially from those expressed in
or implied by such forward-looking statements.These risks and uncertainties
include, among others, the risk that the Scheme is not completed, including
the risk that required shareholder and regulatory approvals for the Scheme may
not be obtained; diversion of management's attention away from other business
concerns; the risks associated with the development, generally, of the
combined company's overall strategic objectives; the ability of the combined
company to build additional value in its business; the existence of
unanticipated technical, commercial or other setbacks related to the combined
company's products and services; and the other risks set forth in the
Prospectus. The combined company may not successfully integrate the operations
of CFR and Adcock Ingram in a timely manner, or at all, and the combined
company may not realize the anticipated benefits or synergies of the Scheme.

Not for release, publication or distribution, in whole or in part, in or into
or from any jurisdiction, where to do so would constitute a violation of the
relevant laws of such jurisdiction.

CONTACT: Enquiries
         Deneb Schiele
         Head of Investor Relations
         Phone +562 2350 5320
         Email dschiele@cfr-corp.com
        
         Media contact
         Amelia Soares
         College Hill South Africa
         Phone: +27 11 447 3030
         Email: Amelia.soares@collegehill.co.za

CFR Pharmaceuticals logo
 
Press spacebar to pause and continue. Press esc to stop.